Prostate cancer (PCa) is the most common worldwide diagnosed malignancy in male
population. The diagnosis, the identification of aggressive disease, and the post-treatment …

The use of prostate-specific membrane antigen (PSMA)-directed applications in modern
prostate cancer management has evolved rapidly over the past few years, helping to …

Background Darolutamide is a potent androgen-receptor inhibitor that has been associated
with increased overall survival among patients with nonmetastatic, castration-resistant …

The microbiota comprises the microorganisms that live in close contact with the host, with
mutual benefit for both counterparts. The contribution of the gut microbiota to the emergence …

PURPOSE BRCA1 or BRCA2 (BRCA) alterations are common in men with metastatic
castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly (ADP …

Rationale The development of consensus guidelines for interpretation of Prostate-Specific
Membrane Antigen (PSMA)-Positron Emission Tomography (PET) is needed to provide …

Background Metastatic castration-resistant prostate cancers are enriched for DNA repair
gene defects (DRDs) that can be susceptible to synthetic lethality through inhibition of PARP …

Background We previously reported that olaparib led to significantly longer imaging-based
progression-free survival than the physician's choice of enzalutamide or abiraterone among …

Background Innovations in imaging and molecular characterisation and the evolution of new
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …

Background Preliminary trial results showed that enzalutamide significantly improved
metastasis-free survival among men who had nonmetastatic, castration-resistant prostate …